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ABSTRACT 
 Three mesoporous silica excipients (Syloid
®
 silicas AL-1 FP, XDP 3050 and XDP 
3150) were formulated with a model drug known for its poor aqueous solubility, namely 
phenylbutazone, in an attempt to enhance the extent and rate of drug dissolution. Although 
other forms of mesoporous silica have been investigated in previous studies, the effect of 
inclusion with these specific Syloid
®
 silica based excipients and more interestingly, with 
phenylbutazone, is unknown. This work reports a significant enhancement for both the 
extent, and rate, of drug release for all three forms of Syloid
®
 silica at a 1:1 drug:silica ratio 
over a period of 30 minutes. An explanation for this increase was determined to be 
conversion to the amorphous form and an enhanced drug loading ability within the pores. 
Differences between the release profiles of the three silicas was concluded to be a 
consequence of the physicochemical differences between the three forms. Overall, this study 
confirms that Syloid
®
 silica based excipients can be used to enhance dissolution, and 
potentially therefore bioavailability, for compounds with poor aqueous solubility, such as 
phenylbutazone. In addition, it has been confirmed that drug release can be carefully tailored 
based on the choice of Syloid
®
 silica and desired release profile. 
KEYWORDS 
Dissolution; Syloid
®
; drug-loading; phenylbutazone; solubility 
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1. INTRODUCTION 
 Mesoporous silica has been shown to exhibit great potential to aid in the formulation 
of pharmaceutical compounds with poor aqueous solubility, as reviewed by Choudhari et al. 
[1]. As a drug carrier system, mesoporous silica can accommodate drugs that have been 
introduced  through organic solvent immersion, incipient wetness impregnation or melted in 
[2]. Specific advantages of using excipients such as mesoporous silicas are their nanoporous 
structures, high surface areas, clinical safety and large pore volumes [3]. Current opinion is 
that substantial progress has been made in recent years in the characterisation and 
development of mesoporous drug delivery systems although more work is needed regarding 
dissolution enhancement potential and related physicochemical properties [4]. There are 
several reasons for this need to continue exploring the possible use of mesoporous silica such 
as practical considerations such as manufacturability to large scale quantities (e.g. tonne) and 
regulation, as well as physicochemical considerations such as the possibility of re-adsorption 
onto the silica surface [4]. Adsorption of small drug particles on the surface of large 
excipients has been a successful strategy for low-dose drugs, poorly water soluble drugs, 
targeted drug release [5], sustained drug delivery [6] and stability enhancement. This is 
mainly a result of improving the dissolution profile by increasing drug surface area or 
transformation of the drug from a crystalline to amorphous form [7] and its ability to be 
retained within the silica pores [8]. In many cases, the method of formulation can be critical 
in defining the properties of the resultant formulation, for example silica-based drug delivery 
vehicles have been investigated to avoid hydrolisation of the active using supercritical CO2[9, 
10], a formulation method which is known for its high drug-loading ability [11] amongst 
other advantages [12]. Several other formulation methods have also been attempted, for 
example, to create liquid (also known as liquisolid) formulations [13] and pediatric (solvent 
free) formulations [14] as well as work within our group that has previously confirmed the 
3 
 
application of microwave irradiation for mesoporous silicas [15]. Furthermore, there is 
clearly an interest in developing mesoporous silica formulations as evidenced by recent work 
to predict in vivo performance, for example, using in silico techniques [16], to overcome 
multidrug resistance [17] as well as ameliorating toxic side effects [18]. 
 One particular category of mesoporous silicas where only very limited studies have 
been conducted to date are regarding Syloid
®
 silica based formulations. These forms of silica 
have a highly developed network of mesopores that provide access to the large surface area, 
i.e. a combination of a high adsorption capacity, along with a desirable pore size and surface 
morphology. For these reasons, these silicas tend to be used to improve the flow properties of 
pharmaceuticals where liquid ingredients can be converted into free-flowing powders. 
Although these properties are beneficial, their suitability to enhance dissolution has only 
briefly been considered (by publication) for two forms of Syloid
®
 silica (244 and AL-1) with 
two model drugs, namely indomethacin [19] and itraconazole [20]. Interesting, for both 
compounds an enhancement in the rate, and extent of dissolution was observed in both 
studies. Yet surprisingly, other forms of Syloid
®
 silica have not yet been considered even 
though they may provide a plethora of advantages for drug-loading formulations.  
 One specific drug renowned for having poor aqueous solubility: 0.05 mg/mL [21], 
and therefore problematic dissolution with potentially low bioavailability, is phenylbutazone. 
This particular compound is commonly used in equine environments as a nonsteroidal anti-
inflammatory drug (NSAID)[22, 23], often prescribed for pain control [24, 25]. Although 
drug solubility is significantly greater in ethanol and 1-octanol [26], the low level of aqueous 
solubility results in complications for formulators. One study has successfully enhanced the 
dissolution through the creation of a solid dispersion with polyethylene glycol 8000 [27] and 
another with SBA-15 [28], yet there is still a clear need for developing alternative 
formulations that can achieve an even greater enhancement in release of the active 
4 
 
compound. Phenylbutazone is an excellent candidate for exploring the potential to enhance 
solubility through formulation with a dissolution-limiting low solubility yet incredibly 
significant usage within the equine community. This is because many of the present 
formulations available on the market tend to be unfavourable with issues surrounding drug 
delivery and poor palatability [29] thus ways to enhance phenylbutazone-based formulations 
are highly desirable. 
 This work investigates the suitability of using three types of Syloid
®
 silica based 
excipients to quantify their potential to enhance the rate of dissolution of phenylbutazone and 
determine the causes of any enhancements observed. 
2. MATERIALS AND METHODS 
2.1 Materials  
Phenylbutazone, potassium phosphate dibasic, potassium phosphate monobasic (all ≥ 99 %) 
were purchased from Sigma Aldrich (Dorset, UK) and used as received. Syloid
®
 silicas (AL-
1 FP, XDP 3050 and XDP 3150) were kindly donated by Glantreo Ltd, Cork, Ireland and W. 
R. Grace & Co, Maryland, USA. Table 1 provides a summary of the physicochemical 
properties of the Syloid
®
 silicas, the data presented was determined using nitrogen gas 
sorption isotherms. These were measured at 77 K using a Micromeritics TriStar II surface 
area analyzer (Micromeritics, Norcross, GA, USA). Samples were pre-treated by heating at 
200 °C under nitrogen for 12 hours. The surface area was measured using the Brunauer-
Emmett-Teller (BET) method. The pore volume and pore diameter data was calculated using 
the Barrett, Joyner and Halenda (BJH) method [2]. Specific surface areas were calculated 
from the measured relative pressure in the range of P/P0 = 0.01 to P/P0 = 0.3. Mesoporous 
volumes were estimated from the volume of nitrogen adsorbed after the micropores have 
been filled until after condensation into the mesopores was complete. Of particular interest is 
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the range of surface areas and pore volumes exhibited by the three Syloid
®
 silicas as based on 
previous research, such properties may influence dissolution, for example, pore size has been 
known to effect drug release profiles for other mesoporous systems [30]. 
2.2 Methods 
2.2.1 Formulation Methods 
200 mg of Syloid
®
 silica XDP 3050 was placed in a beaker whereupon 40 mL of deionised 
water was gradually added followed by 200 mg of phenylbutazone to achieve a total drug and 
silica mass of 400 mg. Over a period of sixty minutes the solution was stirred and heated to a 
maximum of 90 ºC, cooled to room temperature, vacuum filtered and dried overnight at 60 ºC 
then sieved to remove agglomerates larger than 250 µm. This process was repeated in 
triplicate and then with the replacement of XDP 3050 with XDP 3150 and AL-1 FP to 
produce a total of three unique drug-Syloid
®
 silica formulations. A series of variable ratios of 
drug:Syloid
®
 silica formulations were also formulated but based on dissolution profile data 
(not shown), no significant differences in release profiles were observed between the 
formulations thus this paper only presents formulations at a 1:1 ratio. A final formulation was 
produced that involved phenylbutazone undergoing the formulation process (but without the 
presence of Syloid
® 
silica) to determine if it was the processing that affected dissolution or 
the presence of each Syloid
®
 silica itself. Water was used as a ‘carrier’ to disperse the drug 
within the mixture, rather than dissolving the drug with organic solvent, this was followed by 
heating to help achieve maximum dispersion within the mixture. 
2.2.2 Characterisation Methods 
Powder X-ray diffraction data were collected on a Bruker D2-Phaser equipped with a Cu Kα1 
radiation source at 30 kV and 10 mA current. Particle size distribution of the formulated 
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products was analysed using a Malvern Mastersizer 2000 (Worcestershire, UK) using 5 – 10 
mg of powder per sample with one drop of surfactant (IGEPAL
®
 CA-630) at a stirring speed 
of 2000 rpm. Triplicate data was subsequently analysed using Mastersizer 2000 software 
(V5.61). Drug loading was verified to be 100 % in all formulated samples by UV analysis of 
the filtrates (λ = 282 nm) with no residual drug detected (< 1 %), thus confirming all of the 
drug remained within the formulation (rather than washed away with the filtrate during the 
formulation process). For stability confirmation the infrared spectrum for the pure samples 
and their formulations was recorded using a Nicolet-380 Fourier Transform Infrared 
spectrometer (FT-IR) with an ATR crystal. Powder samples were placed directly onto the 
diamond crystal and the anvil lowered to ensure that sample was in full contact with the 
diamond. Each spectrum was obtained in the range of 500 – 4000 cm-1 with 2 cm-1 resolution. 
In this study, the morphology of the prepared samples was characterised using scanning 
electron microscopy (SEM), (JEOL JSM-6060LV, Japan) with gold-plating using a sputter 
coater (SC7620) prior to imaging.  
2.2.3 In vitro phenylbutazone release 
Dissolution profiles were determined using a USP Type II (paddle method) PharmaTest 
DT70 system, with manual sampling for a period of 30 minutes. Formulated samples with a 
total drug content of 22.5 mg were placed in 900 mL of pH 7.0 phosphate buffer, stirred at 75 
rpm and maintained at 37.0 ± 0.5 ºC, maintaining sink conditions throughout the duration of 
the experiment. Filtered samples were removed every 5 minutes, replaced with phosphate 
buffer, and analysed using UV spectroscopy (Cary 60, Agilent) set at a wavelength (λ) of 282 
nm with conversion to percentage drug release using a standard calibration plot. Samples 
were analysed in triplicate to determine mean drug release percentages and associated error 
limits.  
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3. RESULTS AND DISCUSSION 
3.1 Characterisation of formulations 
XRD samples of the three mesoporous silicas both with, and without, the presence of 
phenylbutazone are shown in Figure 1. Previous XRD studies using naproxen noted that the 
diminishment of peak intensities confirmed that the drug had loaded into channels of a 
mesoporous material [31], resulting in an amorphous formulation with an absence of 
characteristic peaks [15]. A similar result was observed in this work whereby the purely 
crystalline phenylbutazone that could be seen in Figure 1A (and after processing in Figure 
1B), was converted to the amorphous form following formulation with the three Syloid
®
 
silicas (Figures 1C-1E). As discussed earlier, from analysing the filtrates and confirming all 
of the drug had remained within the formulation, the absence of peaks cannot be explained by 
a reduced concentration of drug and can only be explained by a transformation to the 
amorphous form. 
Particle size analysis confirmed phenylbutazone (prior to formulation) exhibited an average 
particle size of 65 – 70 µm. The size of the three Syloid® silicas prior to formulation are 
presented in Table 1 and were confirmed in this study to have average values of 10, 50 and 
110µm for AL-1 FP, XDP 3050 and 3150 respectively. These three Syloid
®
 silicas display an 
interesting range of particle sizes prior to formulation yet their subsequent dissolution profiles 
may actually be more dependent upon their size after formulation (through the formation of 
aggregates) therefore it is this parameter that is of interest in this work. Firstly, AL-1 FP 
displayed an increase in the average particle size and a slightly broader distribution of sizes 
with the majority of particles between 5 and 100 µm after formulation. Secondly, a similar 
result was seen for XDP 3050 with the majority of particles between 40 and 100 µm. An 
explanation for this increase in size and diversity of sizes for both Syloid
®
 silicas is most 
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likely a consequence of particle agglomeration as a result of drug incorporation and/or 
processing effects. Thirdly, Syloid
®
 silica 3150 did not exhibit any significant increase in 
average particle size following formulation although there was an increase in the 
polydispersity of particle size. Again, this indicates agglomeration may have occurred to a 
limited extent but not to the same degree as that seen for the other Syloid
® 
silicas.  
FT-IR spectroscopy was used to monitor the presence of phenylbutazone and determine 
interactions with the three silicas (Figure 2 and 3). Analysis of spectra for phenylbutazone 
showed the expected absorption bands at wavenumbers (with corresponding functional 
groups) of 754 and 1483 cm
-1
 (C-H), 1270 cm
-1
 (C-N) and 1720 cm
−1
 (C=O). Analysis of the 
spectra for phenylbutazone subjected to the processing method did not reveal any changes in 
the specific absorption bands for the drug, suggesting a lack of degradation as a result of the 
formulation process. The three Syloid® silicas were analysed using FT-IR spectroscopy and 
all displayed the expected intense Si-O absorption band at 1060-1070 cm
-1 
[32]. For the three 
phenylbutazone-silica formulated products, the results indicated a significant disappearance 
of the drug, mainly displaying spectra corresponding to just each type of silica present. 
Furthermore, the spectra did not display any obvious additional peaks thus indicating there 
had been no significant changes in the chemical structure or drug-silica interactions.  
Surface morphologies of the pure phenylbutazone and the three Syloid
®
 silicas prior to 
formulation, processed phenylbutazone, Syloid® silica-based formulations – XDP 3050, 
XDP 3150 and AL1 FP are presented in Figures 4 and 5. The drug’s crystalline state, along 
with the disordered irregular shapes of AL 1 FP, XDP 3150, and XDP 3050 silicas was 
evident by SEM (Figure 4). The SEM image confirmed the insignificant effect of processed 
phenylbutazone as the drug retained a crystalline structure. However, there was a uniform 
distribution of phenylbutazone on the surface of AL 1 FP due to a larger surface area, smaller 
pore volume and pore diameter. For Syloid® XDP 3150 and XDP 3050 based formulations, 
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there was an even distribution of the former particles with phenylbutazone particles reduced 
in size while for the latter, more of the drug was confined in the pores and on the surface, 
visible in the SEM images (Figure 5).        
3.2 In vitro phenylbutazone release 
Dissolution profiles of phenylbutazone loaded Syloid
®
 silicas were investigated for a period 
of thirty minutes in pH 7.0 phosphate buffer. As can be seen in Figure 6, pure 
phenylbutazone that had not undergone the formulation process exhibited 7.2 % (± 1.4 %) 
drug release after five minutes yet only increased to a maximum of 43.7 % (± 2.3 %) release 
after thirty minutes. For many drugs, this low percentage of drug release after this time would 
be deemed unsuitably low and may limit bioavailability. Through undertaking the 
formulation process with the drug alone, i.e. hydration, heating, filtering, drying then sieving, 
the percentage of drug release, or more accurately in this case, dissolution after thirty minutes 
was 43.8 % (± 7.9 %). Therefore, it has been confirmed that exposure of the drug to the 
formulation process did not affect the profile observed, i.e. hydrating through to sieving did 
not enhance the effects observed for phenylbutazone. All three Syloid
® 
silica based 
formulations exhibited a dramatic enhancement in percentage dissolution, confirming that the 
presence of Syloid
®
 silica contributed to the increase. Firstly, XDP 3150 achieved a 
percentage release of 42.4 % (± 1.9 %) after only five minutes, i.e. almost equal to that 
observed for drug alone after twice as long. After a period of thirty minutes this value had 
increased to 78.3 % (± 2.2 %), far higher than that seen for drug alone or drug that had 
undergone the formulation process. Secondly, Syloid
®
 silicas AL1 FP did not show such a 
promising percentage release after five minutes (30.2 % (± 1.2 %)) compared with XDP 
3150, yet after a total of thirty minutes had exceeded the former Syloid
®
 silica to reach a 
maximum percentage release of 86.0 % (± 4.2 %). Finally, XDP 3050 was found to be the 
most successful Syloid
®
 silica for enhancing percentage release with an impressive 49.4 % (± 
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0.8 %) released after five minutes, i.e. greater than the total seen for pure drug after thirty 
minutes, increasing to a maximum of 99.6 % (± 3.0 %) release after thirty minutes.  
When determining why all three Syloid
®
 silicas have enhanced the percentage of dissolution 
following a standard formulation method, it would appear that the transformation from the 
crystalline to amorphous form (as evidenced by XRD and dissolution profiles of processed 
samples) plays a key role. This has been the conclusion of other researchers, when 
investigating alternative mesoporous materials [31], and fits well with the results from this 
work. However, when considering why the three Syloid
®
 silicas did not facilitate the same 
increase in percentage release, it is more appropriate to consider their relative 
physicochemical properties, specifically those identified in Table 1. For example, AL1 FP 
and XDP 3050 pore sizes are very different, in that AL1 FP has small mesopores, i.e. a 
smaller pore volume and diameter compared with XDP 3050. Based on the pattern of 
increasing percentage release, i.e. from XDP 3150 to AL1 FP to XDP 3050, it would appear 
that two properties of the Syloid
®
 silicas may play a key role in controlling the process, 
namely surface area and/or pore diameter. Interestingly, pore volume does not appear to be an 
influential factor for the rate and extent of dissolution yet pore diameter is. In this work it 
appears that a large pore diameter, with a small surface area, maximises the extent of 
dissolution, which again, fits well with the findings of other studies with mesoporous 
microspheres [30, 33]. As a consequence of this, it is not only possible to dramatically 
enhance the rate and extent of dissolution, but also to vary the percentage depending upon the 
type of Syloid
®
 silica used. Another potentially influential factor is the formation of 
aggregates which may affect the drug release profile through the creation of particle 
aggregation. If this is the case then it can be proposed that there are two unique structures 
within the formulation: drug within pores and aggregates between particles which can both 
contribute to drug release.  
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4. CONCLUSIONS  
 In summary, it has been confirmed that it is possible to formulate Syloid
® 
silica based 
formulations to enhance the dissolution of a poorly soluble drug, in this case, 
phenylbutazone. Characterisation data implies this enhancement is a result of a change in 
crystallinity and the ability of the drug to enter pores within the Syloid
®
 silica structure. All 
three Syloid
®
 silicas analysed demonstrated a dramatic increase in percentage release with 
their final percentage values linked to the Syloid
®
 silica pore diameter and/or surface area. 
This finding can be of benefit for not only phenylbutazone-based equine formulations but 
potentially a far wider range of compounds that exhibit poor aqueous solubility which will 
help alleviate bioavailability issues. To ensure that long term stability is not a limiting factor 
for formulation possibilities, it is the intended subject of future sample analysis, using 
techniques such as XRD and SEM.  
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Table 1: The physicochemical properties of the Syloid® silicas used in this study 
Name 
Mean 
Particle 
Size (µm) Shape 
Surface Area 
(m2/g) 
Pore Volume 
(cm3/g) 
Pore Diameter 
(Å) 
AL-1 FP 10 Irregular 605 0.23 26 
Syloid XDP 3050 50 Irregular 287 1.69 229 
Syloid 3150 110  Irregular 320 1.70 200 
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Figure 1. XRD patterns for A) phenylbutazone, B) processed phenylbutazone, C) 
phenylbutazone and AL1 FP, D) phenylbutazone and XDP 3150, and E) phenylbutazone and 
XDP 3050. 
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Figure 2. FT-IR analysis of A) phenylbutazone B) AL 1 FP, C) XDP 3150 and D) XDP 3050 
silicas prior to formulation 
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Figure 3. FT-IR analysis of A) phenylbutazone B) processed phenylbutazone, C) 
phenylbutazone and AL 1 FP, D) phenylbutazone and XDP 3150 and E) phenylbutazone and 
XDP 3050 silicas after formulation 
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Figure 4. Scanning electron micrographs for particles of A) phenylbutazone B) AL 1 FP, C) 
XDP 3150 and D) XDP 3050 silicas prior to formulation 
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Figure 5. Scanning electron microscope images (SEM) of A) processed phenylbutazone, B) 
phenylbutazone and AL1 FP, C) phenylbutazone and XDP 3150, and D) phenylbutazone and 
XDP 3050 after formulations. 
 
Figure 6. Phenylbutazone release profiles for phenylbutazone (PhB), processed 
phenylbutazone, Syloid® silica based formulations – XDP 3050, XDP 3150 and AL1 FP. 
Each datapoint represents the mean of triplicate results (±SD). 
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